Current Editions
Don’t sleep on China’s academic innovation: a Perspective
Forget the ‘fast follower’ narrative: Plenty of new target biology is now coming from Chinese university labs
Editor's Commentary
Product Development
Novo’s market cap slims down on CagriSema obesity data
Placebo-adjusted weight loss falls short of 25%+ expectations, doesn’t differentiate from Lilly’s Zepbound
Emerging Company Profile
City: Taking RNAi beyond the liver
Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
Politics, Policy & Law
Three strikes and kids’ cancer is out
Pediatric priority review vouchers end at midnight tonight as House passes latest version of spending bill
Deals
The rising tide of billion dollar biotech M&A
An analysis of $1B+ takeouts in 2016-24 finds biotechs opting for the billion dollar exit door in robust numbers
BioCentury ISSN 1097-7201